Biotechnology

Amgen

Daiwa Securities Downgrades Amgen's Target Price to $390.00

Amgen Advances Obesity Drug MariTide to Phase III Trial

Amgen Invests in Expanding Its Research Center to Accelerate Drug Development

Amgen Adds $300M to US Manufacturing Investments and Expands Puerto Rico Plant

BMO Capital Maintains Buy Rating on Amgen with $400 Price Target

Guggenheim lowers Amgen's target price to $340

Amgen's stock price falls 6.1% due to tax litigation

US Bank Analyst Maintains Sell Rating on Amgen

Morgan Stanley analyst maintains hold rating for Amgen with a target of $332

FDA accuses Amgen of data falsification in Avacopan and demands recall

Amgen released FY2026 Q1 earnings on April 30 After-Market (EST), actual revenue USD 8.618 B (forecast USD 8.571 B), actual EPS USD 3.34 (forecast USD 3.0205)

Amgen Reports Q1 2026 Earnings and Revenue Growth

Amgen Shares Up Ahead of Expected Q1 Earnings Growth

FDA considers revoking approval of Amgen's drug Tavneos

Amgen to Release FY2026 Q1 Earnings on April 30 During-Market EST, Forecast Revenue USD 8.582 B, EPS USD 3.0006

Bernstein Analyst Maintains Hold Rating on Amgen with $335 Price Target

Amgen's Lung Cancer Drug Tarlatamab Approved by China's National Medical Products Administration

Guggenheim raises Amgen price target to $351 and maintains neutral rating

Truist Securities Raises Amgen's Target Price to $325 and Maintains Hold Rating

Amgen Announces Positive Phase 3 Clinical Trial Results for TEPEZZA® in Adult Patients with Moderate to Severe Active Thyroid Eye Disease

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

AMGN

ARKG

LABU

IBBQ

SBIO

Amgen has maintained stable performance in the biotechnology sector, with its stock price recently rising slightly by 1.96% amid market turbulence. With the changing global health demands, particularly in the context of increased attention to chronic and rare diseases, Amgen's business has sustainable growth potential. Recently, Amgen has made significant progress in research and development investments and strategic partnerships. In the biotechnology field, continuous innovation and the expansion of its product portfolio have enabled the company to occupy a favorable position in the competition. Meanwhile, the rise in stock price also reflects the market's recognition of its future growth potential. Technically, the emergence of bullish signals in MACD, combined with recent stock price performance and trading volume, seems to indicate an improvement in market expectations for Amgen. Therefore, investors should closely monitor changes in chemotherapy innovations and the timing of new drug launches to capture potential rebound opportunities in stock prices. In the short term, Amgen's performance will be driven by key factors such as R&D progress and the approval status of new therapies. This article provides only technical analysis and market information for reference and does not constitute any investment advice. The market carries risks, and investments should be made with caution

Technical Forecast

First Trust NYSE Arca Biotech Index Fd

Ark Genomic Revolution ETF

Health Care Select Sector SPDR

Direxion S&P Biotech Bull 3X

VG Health

Invesco Nasdaq Biotechnology ETF

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

ALPS Medical Breakthrough

iShares Biotechnology ETF

VanEck Biotech ETF

iShares US Pharma

iShares Global Healthcare

Pre-market Trend | Amgen (AMGN.US)

Amgen announced a CFO transition, with Peter Griffith retiring on Aug. 31, 2026, after strengthening the company's financial foundation. Thomas Dittrich will succeed him as CFO on Sept. 1, 2026. The board's decision reflects Amgen's commitment to experienced leadership for long-term growth. Current analyst ratings for AMGN stock indicate a Buy with a price target of $427.00, though Spark's AI Analyst rates it as Neutral due to elevated leverage and fair valuation.

Tip Ranks

Dow Jones Industrial Average

NASDAQ-100

Amgen Announces CFO Transition and Leadership Succession Plan

Amgen Inc. (AMGN) shares rose 1.96% to $330.75 on a weak trading day for the market, breaking a three-day losing streak. Despite this gain, the stock remains 15.47% below its 52-week high of $391.29. Competitors like Johnson & Johnson, Pfizer, and AbbVie also saw gains, with trading volume surpassing its 50-day average.

MarketWatch Automated

S&P 500

Johnson & Johnson

Pfizer

Abbvie

Factset Research

Amgen Inc. Stock Outperforms Competitors On Strong Trading Day

AMGEN ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER PETER GRIFFITH | AMGN Stock News

StockTitan

AMGEN ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER PETER GRIFFITH | AMGN Stock News

4547

Amgen's Japanese partner, Kissei Pharmaceutical, has advised doctors to avoid prescribing Tavneos to new patients due to safety concerns following FDA warnings about liver injuries. Kissei is urging a reassessment of current patients' treatment amid scrutiny over trial data integrity. The FDA proposed withdrawing Tavneos' approval, citing manipulated data in clinical trials. Kissei is coordinating with Japanese health authorities to ensure patient safety while the drug remains approved in Japan.

benzinga_article

Kissei Pharmaceutical Co., Ltd.

Nichi-Iko Pharmaceutical Co., Ltd.

Churchill Capital XI

Amgen Japanese Partner Urges Caution On Tavneos Use

GLOBALT Investments LLC GA increased its stake in Amgen Inc. by 25.4% in Q4, owning 25,923 shares valued at $8.49 million. Other institutional investors also adjusted their positions in Amgen. The company reported $5.15 EPS for the last quarter, exceeding estimates, and declared a quarterly dividend of $2.52 per share. Analysts have varied price targets for Amgen, with ratings ranging from Strong Buy to Sell.

Market Beat

Deutsche Bank AG

Truist Financial

UBS Group AG

Piper Sandler Cos

Deutsche Bank AG Subscription Rights

Deutsche Postbank AG

GLOBALT Investments LLC GA Has $8.49 Million Stock Holdings in Amgen Inc. $AMGN

Amgen(AMGN.US)

Pre-market Trend | Amgen (AMGN.US)

Amgen Announces CFO Transition and Leadership Succession Plan

Amgen Inc. Stock Outperforms Competitors On Strong Trading Day

AMGEN ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER PETER GRIFFITH | AMGN Stock News

Amgen Japanese Partner Urges Caution On Tavneos Use

GLOBALT Investments LLC GA Has $8.49 Million Stock Holdings in Amgen Inc. $AMGN